Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04510129 · ClinicalTrials.gov registry record
A Multicenter Cancer Biospecimen Collection Study
A clinical trial of Cervical Cancer and Hepatocellular Carcinoma, sponsored by Cofactor Genomics.
- Recruiting
- Registry status
- 1,650
- Enrollment target
- 1
- Study location
NCT04510129: Recruiting study of Cervical Cancer and Hepatocellular Carcinoma, sponsored by Cofactor Genomics.
NCT04510129 is a study of Cervical Cancer and Hepatocellular Carcinoma that is actively recruiting participants, run by Cofactor Genomics. The registered enrollment target is 1,650 participants, above the 559-participant average among 144 other Cervical Cancer trials with a reported enrollment target (195% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04510129, a study of Cervical Cancer and Hepatocellular Carcinoma, is actively recruiting participants, sponsored by Cofactor Genomics.
- RECRUITING
- Registry status
- 1,650 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will collect de-identified tumor samples, with correlated clinical/demographic data and tissue histology, from patients selected or scheduled for pre-treatment tumor biopsy or who have had a recent pre-treatment tumor biopsy. These specimens and clinical data may be used in subsequent studies for the development and validation of a diagnostic test.
Primary Outcome
No response to treatment with PD-L1/PD-1 inhibitor and response to treatment with PD-L1/PD-1 inhibitor.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST OncoPrism™ assay
Study Locations (1)
California
- Curebase - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,650 participants |
| Start Date | 2020-02-05 |
| Est. Completion | 2027-02 |
What NCT04510129 shows while recruiting
NCT04510129 is an observational study that tracks outcomes without assigning an intervention. Its 1,650 participants enrollment target places it among the larger protocols in the corpus, above the 559-participant average among 144 other Cervical Cancer trials with a reported enrollment target (195% higher).
The record links to 10 conditions, with Cervical Cancer appearing as the primary indexed condition, and to 1 intervention - of which OncoPrism™ assay is the first listed.
NCT04510129 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04510129 about?
NCT04510129 is a clinical study titled "A Multicenter Cancer Biospecimen Collection Study". This study will collect de-identified tumor samples, with correlated clinical/demographic data and tissue histology, from patients selected or scheduled for pre-treatment tumor biopsy or who have had a recent pre-treatment tumor biopsy. These specimens and clinical data may be used in subsequent stu...
What is the current status of trial NCT04510129?
This trial is currently recruiting. The enrollment target is 1,650 participants. The study started on 2020-02-05. Estimated completion is 2027-02.
What conditions does trial NCT04510129 study?
This clinical trial studies the following conditions: Cervical Cancer, Hepatocellular Carcinoma, Renal Cell Carcinoma, Triple Negative Breast Cancer, Urothelial Carcinoma.
What interventions are being tested in trial NCT04510129?
The interventions under investigation include: OncoPrism™ assay (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04510129?
This trial is sponsored by Cofactor Genomics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04510129 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cervical Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04510129's enrollment target sits among peer trials
1,650 12th of 144 higher than 133 of 144 other Cervical Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cervical Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Biological Drivers of Cervical Cancer and Side Effects From Radiation Therapy
RECRUITING
-
PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer
RECRUITING · Phase 2
-
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 2
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
-
PopSci CHW4CervixHealth
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05612750 · 1,650 participants · NA
Comparative Effectiveness of Online 8-session CBT vs. 1-Session Empowered Relief for Chronic Pain - The PROGRESS Study
- NCT06215716 · 1,650 participants · Phase 3
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
- NCT07046260 · 1,650 participants
Prospective Study to Assess a Diagnostic Aid for Cancer
- NCT06401330 · 1,656 participants · Phase 3
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI